NCT02853331 2026-02-02
KEYNOTE-426
Merck Sharp & Dohme LLC
Phase 3 Completed
Clinical Trials
90 trialsNCT04394975 2025-11-28
Study to Evaluate the Efficacy and Safety of Toripalimab in Combination With Axitinib Versus Sunitinib Monotherapy in Advanced Renal Cell Cancer
Shanghai Junshi Bioscience Co., Ltd.
Phase 3 Completed
NCT00930033 2025-09-05
CARMENA
Assistance Publique - Hôpitaux de Paris
Phase 3 Completed
NCT02684006 2025-07-30
JAVELIN Renal 101
Pfizer
Phase 3 Completed
NCT03260894 2025-07-29
Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)
Incyte Corporation
Phase 3 Completed
NCT02231749 2025-06-26
Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)
Bristol-Myers Squibb
Phase 3 Completed
NCT00720941 2025-03-30
COMPARZ
Novartis
Phase 3 Completed
NCT01147822 2025-03-28
Pazopanib Versus Sunitinib in the Treatment of Asian Subjects With Locally Advanced and/or Metastatic Renal Cell Carcinoma
Novartis
Phase 2 Completed
NCT02761057 2025-01-13
Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed
National Cancer Institute (NCI)
Phase 2 Completed
NCT03109015 2024-10-08
ASSET
Duke University
Phase 2 Completed
NCT05745142 2024-08-05
A Study to go Back Into Records and Observe How People With Metastatic Renal Cell Carcinoma (mRCC) Who Received a Medicine Called Sunitinib Responded to This Medicine.
Pfizer
Completed
NCT01517243 2023-09-21
Phase II Study of Alternating Sunitinib and Temsirolimus
Dartmouth-Hitchcock Medical Center
Phase 2 Completed
NCT01164228 2023-06-15
Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT00716625 2023-05-03
Special Investigation For Renal Cell Carcinoma (RCC) Of Sunitinib Malate (Regulatory Post Marketing Commitment Plan)
Pfizer
Completed
NCT04175262 2023-05-03
Clinical Outcomes For Patients With Metastatic Renal Cell Carcinoma (mRCC) Who Received Sunitinib After 1st Line Immune-oncology (IO) Treatments
Pfizer
Completed
NCT05800106 2023-04-10
A Bioequivalence Study of Sunitinib Malate Capsules.
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1 Completed
NCT04076787 2023-04-06
Clinical Outcomes for Patients With Renal Cell Carcinoma Who Received First-Line Sunitinib
Pfizer
Completed
NCT02420821 2023-01-30
IMmotion151
Hoffmann-La Roche
Phase 3 Completed
NCT02432846 2022-08-22
MERECA
Mendus
Phase 2 Completed
NCT01664182 2022-06-07
Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT04115189 2022-05-10
A Retrospective Medical Record Review of First-Line Sunitinib Administration Schedules and Outcomes Among Patients With mRCC in Latin America (LA)
Pfizer
Completed
NCT01472081 2021-12-02
Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) (CheckMate 016)
Bristol-Myers Squibb
Phase 1 Completed
NCT02960906 2021-04-26
BIONIKK
Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie
Phase 2 Completed
NCT00541008 2021-02-21
Sunitinib as First-Line Therapy in Treating Patients With Locally Advanced Metastatic Papillary Renal Cell Cancer
UNICANCER
Phase 2 Completed
NCT01835158 2021-02-11
Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT02555748 2021-01-12
SUP-R
Institut Claudius Regaud
Phase 4 Completed
NCT03066427 2020-11-13
INMUNOSUN
Spanish Oncology Genito-Urinary Group
Phase 2 Completed
NCT02060370 2020-02-27
Sunitinib Scheduling in Metastatic Renal Cell Carcinoma (mRCC)
M.D. Anderson Cancer Center
Phase 2 Completed
NCT03379012 2019-10-22
FARETES
Kidney Cancer Research Bureau
Phase 2 Completed
NCT00794950 2019-09-23
Sutent
University of Michigan
Phase 2 Completed
NCT03519542 2019-09-18
SOGANG
Spanish Oncology Genito-Urinary Group
Completed
NCT00428220 2019-06-27
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
Pfizer
Phase NA Completed
NCT00526656 2019-04-16
Sunitinib in Treating Patients With Locally Advanced Bladder Cancer
Case Comprehensive Cancer Center
Phase 2 Completed
NCT01258348 2019-01-10
A Phase 1b Trial in Patients With Renal Cell Cancer
Eli Lilly and Company
Phase 1 Completed
NCT01089088 2018-10-26
Gemcitabine Hydrochloride, Cisplatin, and Sunitinib Malate as First-Line Therapy in Treating Patients With Locally Advanced And/or Metastatic Transitional Cell Carcinoma of the Urothelium (SUCCINCT)
Cardiff University
Phase 2 Completed
NCT00599313 2018-10-25
Phase II Sunitinib Prog Met AIPC
US Oncology Research
Phase 2 Completed
NCT00375674 2018-09-21
S-TRAC
Pfizer
Phase 3 Completed
NCT01158222 2018-09-14
Sunitinib Malate in Treating Patients With Previously Untreated Metastatic Kidney Cancer
Case Comprehensive Cancer Center
Phase 2 Completed
NCT01829841 2018-05-03
A Study of Famitinib in Patients With Advanced Metastatic Renal Cell Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 2 Completed
NCT01499121 2018-03-06
Study of Efficacy and Safety of Sunitinib Given on an Individualized Schedule
Sunnybrook Health Sciences Centre
Phase 2 Completed
NCT01265901 2017-10-12
IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinoma
Immatics Biotechnologies GmbH
Phase 3 Completed
NCT00499135 2017-10-10
Sunitinib Malate in Treating Patients With Unresectable or Metastatic Kidney Cancer or Other Advanced Solid Tumors
National Cancer Institute (NCI)
Phase 1 Completed
NCT00537056 2017-06-14
Evaluating Sunitinib Therapy in Renal Cell Carcinoma Using F-18 FDG PET/CT and DCE MRI
Stanford University
Phase NA Completed
NCT00425386 2017-05-03
Sunitinib and Erlotinib in Treating Patients With Unresectable or Metastatic Kidney Cancer
OHSU Knight Cancer Institute
Phase 2 Completed
NCT01064310 2017-04-17
PISCES
Novartis
Phase 3 Completed
NCT00617253 2017-03-01
Combination of Recombinant Human IL-21 (rIL-21) and Sunitinib in Stage IV Renal Cell Carcinoma Patients
Novo Nordisk A/S
Phase 2 Completed
NCT00943839 2016-11-10
Sunitinib Malate in Treating Patients With Kidney Cancer
Centre Antoine Lacassagne
Phase NA Completed
NCT00903175 2016-11-08
RECORD-3
Novartis
Phase 2 Completed
NCT00821327 2016-10-25
Gemzar, Cisp, Sunitinib Urothelial Ca
US Oncology Research
Phase 2 Completed
NCT00465179 2016-06-07
Sunitinib Malate in Patients With Non-Clear Cell Renal Cell Cancer
M.D. Anderson Cancer Center
Phase 2 Completed